CYCLEDOUX
Food supplement declared in France, declaration No 2018-3-292, decision dated 8 March 2018
CYCLEDOUX is a food supplement declared in France. Status: declared in France, may be marketed. 1 point in its composition requires a check (prohibited substance, dose or novel food). 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- MADAME ANNICK SIZUN
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2 gélules par jour
- Directions for use
- 2 gélules par jour le matin avec un verre d'eau
- Intended populations
- Women
- Not recommended (according to the manufacturer)
- Breastfeeding women, History of breast cancer
- Objectives stated by the manufacturer (these are not authorised claims)
- Menstrual cycles
Declaration 286927, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Alchemilla vulgaris L. | Parties aériennes | Extrait sec aqueux | 120 mg |
| Achillea millefolium L. | Parties aériennes | Extrait sec hydroalcoolique | 90 mg |
| Pinus pinaster Aiton | Ecorce | Extrait sec hydroalcoolique | 90 mg |
| Fumaria officinalis L. | Parties aériennes | Extrait sec aqueux | 60 mg |
| Matricaria chamomilla L. | Parties aériennes | Extrait sec aqueux | 30 mg |
| Vitex agnus-castus L. | Fruit | Extrait sec aqueux | 30 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Gluconate de cuivre | Cuivre | 5,000 µg | 2,000 µg |
| Gluconate ferreux | Fer | 40 mg (safe level) | 14 mg |
| L-méthylfolate de calcium | Folates (vitamine B9) | 1,000 µg | 200 µg |
| Oxyde de magnésium | Magnésium | 250 mg | 300 mg |
| Gluconate de manganèse | Manganèse | 8 mg (safe level) | 3.5 mg |
| Levure enrichie en sélénium | Sélénium | 255 µg | 50 µg |
| Chlorhydrate de pyridoxine | Vitamine B6 | 12 mg | 2 mg |
| Gluconate de zinc | Zinc | 25 mg | 15 mg |
Additives
Hydroxypropyl Méthyl Cellulose, E470b, E171
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
L'emploi chez les femmes allaitantes et chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein est déconseillé. Les femmes enceintes et allaitantes sont invitées à prendre l’avis d’un professionnel de santé avant toute supplémentation en vitamines et minéraux.
Regulatory points
- À vérifier
The composition lists additive E171 (titanium dioxide), removed from the list of additives allowed in food, supplements included: since 7 August 2022, a supplement containing it can no longer be placed on the market in the Union. The declaration predates this removal: if the product is still sold, its formula must have changed; check the label.
Source: Regulation (EU) 2022/63: titanium dioxide (E171) removed from the food additives allowed in the EU, règlement (UE) 2022/63.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Matricaria chamomilla L.
Read the warning, when it applies and the studies cited
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).
Cautions and warnings
When using this product exercise caution if you drive or use machinery as you may experience drowsiness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Health Canada monograph dated 19 December 2025
German Chamomile - Matricaria Chamomilla Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Health Canada monograph dated 31 January 2025
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal
Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)
Cautions and warnings
Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Vitex agnus-castus L.
Read the warning, when it applies and the studies cited
CHASTE TREE - VITEX AGNUS-CASTUS
Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
Sources cited by Health Canada (4)
- Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
Contraindications
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
Sources cited by Health Canada (9)
- Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
- Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
- Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.